In this paper we investigated PRRT radiosensitization of NET in in vitro and in vivo models by DNA-PKcs inhibition and showed that selective DNA-PKcs inhibition is a feasible strategy to potentiate the cancer-killing effect of PRRT. The gene discussed is PRKDC; the disease is cancer.